[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1
about
sameAs
New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogsHuman immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analoTSAO-T analogues bearing amino acids at position N-3 of thymine: synthesis and anti-human immunodeficiency virus activityResistance of clinical isolates of human immunodeficiency virus to antiretroviral agents1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activityConformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.Antiviral therapy for human immunodeficiency virus infectionsTreatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.New developments in the chemotherapy of lentivirus (human immunodeficiency virus) infections: sensitivity/resistance of HIV-1 to non-nucleoside HIV-1-specific inhibitors.HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues.What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?Hiv-1 Specific Reverse Transcriptase Inhibitors: why are Tsao-Nucleosides so Unique?Novel Tsao Derivatives. Synthesis and Anti-HIV-1 Activity of Allofuranosyl-TSAO-T Analogues
P2860
Q28367654-14A48CE0-63BF-4BB2-802F-651E57486942Q28368045-CF433E07-B065-4AB2-A43A-1CBC37D561B0Q28371862-8EEA8E5D-C726-417A-9890-486B957291C4Q28378547-D0C3446C-64B0-4CD9-901D-9438DB6EFCABQ28379406-3B130BBC-7AE0-44F0-A2FA-A739F296110DQ34163065-41148FEC-AC9F-4FE1-9F33-8D32CDA0EE41Q35366050-0F235C0C-EFE3-419A-8A04-45C2FCB713D3Q36651931-F5255639-59B6-4E6F-B626-301E132DA598Q36969977-7B6893BA-8929-488C-81CE-840F40BBCFC6Q40390744-3D400C3C-291B-4AA1-AED0-7D9C35D76B24Q40486578-0706A96B-211D-4D24-8DD7-61D5E677DD70Q40672674-46816CED-9127-4310-9E2C-A1627255A32FQ40985925-2798351A-6511-42FC-97DD-C14A8882C51CQ45748524-207641DB-68D8-480F-A2A3-B40262CE4B0EQ57966461-BE26935B-AA28-4355-9FA4-D11E442E1CEEQ57977640-482961A9-0CC8-436F-AEDF-7C176F02E0E5
P2860
[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1
description
1992 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1992
@ast
im Mai 1992 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: May 1992)
@en
vedecký článok (publikovaný 1992-05)
@sk
vědecký článek publikovaný v roce 1992
@cs
wetenschappelijk artikel (gepubliceerd in 1992-05)
@nl
наукова стаття, опублікована в травні 1992
@uk
مقالة علمية (نشرت في مايو 1992)
@ar
name
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@ast
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@en
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@nl
type
label
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@ast
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@en
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@nl
prefLabel
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@ast
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@en
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@nl
P2093
P2860
P356
P1476
[2',5'-Bis-O-(tert-butyldimeth ...... immunodeficiency virus type 1
@en
P2093
A San-Félix
M J Camarasa
M J Pérez-Pérez
S Velazquez
P2860
P304
P356
10.1128/AAC.36.5.1073
P407
P577
1992-05-01T00:00:00Z